R Finch

Summary

Affiliation: University of Nottingham
Country: UK

Publications

  1. ncbi Regulatory opportunities to encourage technology solutions to antibacterial drug resistance
    Roger Finch
    Nottingham University Hospitals, Department of Microbiology and Infectious Diseases, The Clinical Sciences Building, Hucknall Road, Nottingham NG51PB, UK
    J Antimicrob Chemother 66:1945-7. 2011
  2. ncbi Report of working group 2: healthcare needs in the organisation and management of infection
    R Finch
    University of Nottingham, The City Hospital NHS Trust, Nottingham, UK
    Clin Microbiol Infect 11:41-5. 2005
  3. ncbi Educational interventions to improve antibiotic use in the community: report from the International Forum on Antibiotic Resistance (IFAR) colloquium, 2002
    Roger G Finch
    Nottingham City Hospital and University of Nottingham, Nottingham, UK
    Lancet Infect Dis 4:44-53. 2004
  4. ncbi A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections
    Roger G Finch
    Division of Microbiology and Infectious Diseases, The City Hospital, and University of Nottingham, Nottingham, UK
    Clin Microbiol Infect 8:69-91. 2002
  5. ncbi Bacterial resistance--the clinical challenge
    R Finch
    City Hospital and University of Nottingham, Clinical Sciences Building, UK
    Clin Microbiol Infect 8:21-32; discussion 33-5. 2002
  6. ncbi Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment
    R Finch
    Nottingham City Hospital, Nottingham Bayer plc, Newbury, United Kingdom
    Antimicrob Agents Chemother 46:1746-54. 2002
  7. ncbi Community-acquired pneumonia: the evolving challenge
    R Finch
    Division of Microbiology and Infectious Diseases, The City Hospital, Nottingham, UK
    Clin Microbiol Infect 7:30-8. 2001
  8. ncbi Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005
    R Finch
    Division of Microbiology and Infectious Diseases, Molecular Medical Sciences, Clinical Sciences Building, University of Nottingham and Nottingham University Hospitals NHS Trust City Hospital Campus Nottingham NG5 1PB, UK
    J Antimicrob Chemother 58:i3-i22. 2006
  9. ncbi The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria
    S Gander
    Division of Microbiology and Infectious Diseases, School of Clinical Laboratory Sciences, University of Nottingham, The City Hospital, UK
    J Antimicrob Chemother 46:61-7. 2000
  10. ncbi Antibiotic resistance: a view from the prescriber
    Roger G Finch
    Nottingham City Hospital NHS Trust, Department of Microbiology and Infectious Diseases, Clinical Sciences Building, Hucknall Road, Nottingham NG5 1PB, UK
    Nat Rev Microbiol 2:989-94. 2004

Detail Information

Publications13

  1. ncbi Regulatory opportunities to encourage technology solutions to antibacterial drug resistance
    Roger Finch
    Nottingham University Hospitals, Department of Microbiology and Infectious Diseases, The Clinical Sciences Building, Hucknall Road, Nottingham NG51PB, UK
    J Antimicrob Chemother 66:1945-7. 2011
    ....
  2. ncbi Report of working group 2: healthcare needs in the organisation and management of infection
    R Finch
    University of Nottingham, The City Hospital NHS Trust, Nottingham, UK
    Clin Microbiol Infect 11:41-5. 2005
    ..The importance of this topic led to a recommendation that an ESCMID working party be established to investigate the current arrangements of infection services in Europe and to make recommendations for the future organisation...
  3. ncbi Educational interventions to improve antibiotic use in the community: report from the International Forum on Antibiotic Resistance (IFAR) colloquium, 2002
    Roger G Finch
    Nottingham City Hospital and University of Nottingham, Nottingham, UK
    Lancet Infect Dis 4:44-53. 2004
    ..Current research aims include the application of behaviour-change models, the development and validation of prudent antibiotic prescribing standards, and the refinement of tools to assess educational interventions...
  4. ncbi A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections
    Roger G Finch
    Division of Microbiology and Infectious Diseases, The City Hospital, and University of Nottingham, Nottingham, UK
    Clin Microbiol Infect 8:69-91. 2002
    ..Rapid, cost-effective diagnostic techniques are also required and new antibiotics will continue to have a role in disease management...
  5. ncbi Bacterial resistance--the clinical challenge
    R Finch
    City Hospital and University of Nottingham, Clinical Sciences Building, UK
    Clin Microbiol Infect 8:21-32; discussion 33-5. 2002
    ..Frequently the prescriber does not have ready access to the most appropriate data. Integrated strategies to control resistance are urgently needed, as are improved rapid diagnostic facilities...
  6. ncbi Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment
    R Finch
    Nottingham City Hospital, Nottingham Bayer plc, Newbury, United Kingdom
    Antimicrob Agents Chemother 46:1746-54. 2002
    ....
  7. ncbi Community-acquired pneumonia: the evolving challenge
    R Finch
    Division of Microbiology and Infectious Diseases, The City Hospital, Nottingham, UK
    Clin Microbiol Infect 7:30-8. 2001
    ..A once-daily oral dose of telithromycin 800 mg for 7-10 days produces clinical and bacteriological success rates > 90% and equivalent to standard comparator agents, whilst maintaining efficacy against resistant pathogens...
  8. ncbi Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005
    R Finch
    Division of Microbiology and Infectious Diseases, Molecular Medical Sciences, Clinical Sciences Building, University of Nottingham and Nottingham University Hospitals NHS Trust City Hospital Campus Nottingham NG5 1PB, UK
    J Antimicrob Chemother 58:i3-i22. 2006
    ..Modifications to the international regulatory requirements for drug licensing could have a major impact on the time and thus the costs of developing new agents...
  9. ncbi The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria
    S Gander
    Division of Microbiology and Infectious Diseases, School of Clinical Laboratory Sciences, University of Nottingham, The City Hospital, UK
    J Antimicrob Chemother 46:61-7. 2000
    ..However, there were no significant differences in the effects, inhibitory/ bactericidal or recovery times, produced by the two methods of exposure. The two glycopeptides showed a surprising lack of activity...
  10. ncbi Antibiotic resistance: a view from the prescriber
    Roger G Finch
    Nottingham City Hospital NHS Trust, Department of Microbiology and Infectious Diseases, Clinical Sciences Building, Hucknall Road, Nottingham NG5 1PB, UK
    Nat Rev Microbiol 2:989-94. 2004
    ..Remedies necessary for improvements in prudent prescribing include better guidance in managing specific diseases where resistance is of prognostic significance and also increasing diagnostic precision...
  11. ncbi Antimicrobial drug resistance, regulation, and research
    Joshua P Metlay
    VA Medical Center, University of Pennsylvania School of Medicine, Center for Clinical Epidemiology and Biostatistics, Philadelphia, Pennsylvania 19104, USA
    Emerg Infect Dis 12:183-90. 2006
    ..Recent consultations and collaborations between regulators, academics, and industry are welcome. Efforts to coordinate regulatory measures would benefit from greater levels of international dialogue...
  12. ncbi Fusidic acid cream for impetigo. Emergence of resistance to fusidic acid limits its use
    Vivienne C Weston
    BMJ 324:1394. 2002
  13. ncbi Penicillin-resistant pneumococci-implications for management of community-acquired pneumonia and meningitis
    Hisham M Ziglam
    Nottingham City Hospital, Nottingham, UK
    Int J Infect Dis 6:S14-20. 2002
    ..This article reviews current concepts of epidemiology and the implications of penicillin-nonsusceptible pneumococci for management of community-acquired pneumonia and meningitis...